CD154

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Retrieved on: 
Tuesday, April 2, 2024
Janus, Week, CD154, Rheumatoid arthritis, Jaki, Patient, Cohort, KNSA, Joint, Clinical trial, C-reactive protein, CD40, Least squares, Pharmacokinetics, Safety, FDA, Rheumatoid factor, Pharmaceutical industry

HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease. Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.

Key Points: 
  • HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease.
  • Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis.
  • Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.
  • “We believe abiprubart has the potential to provide meaningful benefit to patients suffering from Sjogren’s Disease, a debilitating disorder with no current FDA-approved therapies.

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

Retrieved on: 
Monday, October 30, 2023
Massachusetts General Hospital, Long, Faculty, Orphan drug, Research, American College, Prader–Willi syndrome, Gustav Neuring, Therapy, Obesity, Hydrogen chloride, Binge eating disorder, SL, COVID-19, Smallpox, Pain, Psychiatry, Sumatriptan, MDD, DSM-IV codes, Cell Transplantation, Social anxiety disorder, Upsher-Smith Laboratories, GE, Fibromyalgia, Transplant, MGH, Cancer, Central nervous system, Ischemia, Long COVID, Security (finance), Infection, CD40L, Congress, Survival, Disease, Breakthrough therapy, Animal, Planning, FDA, Autoimmunity, Government, CNS, Neurology, Risk, Science, ACS, PPAR, Annual report, Gujarat University of Transplantation Sciences, Failure, Pharmaceutical industry, Tonix Pharmaceuticals, CD154

CHATHAM, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data from two oral presentations which were delivered recently at the American College of Surgeons (ACS) Clinical Congress 2023, and The International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA), and the Cell Transplant and Regenerative Medicine Society (CTRMS) Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in October 2023. The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection. Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com.

Key Points: 
  • The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection.
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com .
  • include data demonstrating the use of TNX-1500 as maintenance therapy after xeno heart transplant in non-human primates.
  • In both studies, genetically engineered (GE) pigs in baboon transplants were treated with cold-perfused ischemia minimization and a novel costimulation-based immunosuppressive regimen including TNX-1500.

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

Retrieved on: 
Wednesday, October 18, 2023
Massachusetts General Hospital, Faculty, Research, Primate, Gujarat University of Transplantation Sciences, Harvard Medical School, Cadaver, CD40L, Protein engineering, Journal, Tonix Pharmaceuticals, Thrombosis, Columbia, Animal, Transplant, MGH, NIH, Planning, Foundation for the National Institutes of Health, Dietary supplement, Vaccine, CD154, Nature

CHATHAM, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that a study published in the Journal Nature1 by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in collaboration with biotechnology company, eGenesis, utilized TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) as part of the immune modulating regimen to prevent organ transplant rejection. Tonix’s TNX-1500 is in development for the prevention of human kidney organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154.

Key Points: 
  • Tonix’s TNX-1500 is in development for the prevention of human kidney organ transplant rejection.
  • TNX-1500 was invented and developed in-house by Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, and colleagues.
  • Preclinical studies in non-human primates demonstrated that TNX-1500 showed activity in preventing allograft and xenograft organ rejection and was well tolerated.
  • In addition, anti-CD40L monoclonal antibodies have demonstrated efficacy in autoimmune diseases like systemic lupus erythematosus and Sjögren’s Syndrome.”

Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference

Retrieved on: 
Thursday, October 12, 2023
SL, Autoimmunity, Government, Headache, DSM-IV codes, CD40L, Research, Risk, Infection, COVID-19, Binge eating disorder, Smallpox, Central nervous system, Upsher-Smith Laboratories, Fibromyalgia, Hydrogen chloride, Annual report, Prader–Willi syndrome, PPAR, Pain, Obesity, Sumatriptan, Breakthrough therapy, Neurology, Cancer, FDA, Long, IR, Migraine, CNS, MDD, Security (finance), Disease, Therapy, Failure, ThinkEquity, Mandarin Oriental Hotel Group, Long COVID, Gustav Neuring, Social anxiety disorder, Orphan drug, Psychiatry, Conference, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m.

Key Points: 
  • CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the ThinkEquity conference coordinator.
  • A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe

Retrieved on: 
Wednesday, October 11, 2023
SL, Autoimmunity, Government, Medicine, Headache, DSM-IV codes, CD40L, Research, Risk, Infection, COVID-19, Binge eating disorder, Smallpox, Central nervous system, Upsher-Smith Laboratories, Fibromyalgia, Hydrogen chloride, Annual report, Prader–Willi syndrome, PPAR, Pain, Obesity, Sumatriptan, Breakthrough therapy, Neurology, Cancer, CEST, FDA, Long, Migraine, CNS, MDD, Security (finance), Disease, Congress, Therapy, Failure, Long COVID, Gustav Neuring, Science, Social anxiety disorder, Orphan drug, Psychiatry, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.

Key Points: 
  • A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Additional meeting information can be found on the World Vaccine Congress website here .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.

Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering

Retrieved on: 
Friday, September 29, 2023
Long COVID, Prader–Willi syndrome, Sumatriptan, Failure, Telephone, Drug Master File, Autoimmunity, Pain, Acquisition, Madison Avenue, Psychiatry, Therapy, Capital market, SL, Research, Infection, Risk, Orphan drug, Security (finance), FDA, Health, COVID-19, Cancer, Smallpox, Disease, Government, Breakthrough therapy, Hydrogen chloride, MDD, Annual report, Neurology, Form, CD40L, Central nervous system, CNS, Sale, Prospectus, S-3, DSM-IV codes, Nature, Fibromyalgia, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

The closing of the public offering is expected to take place on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the public offering is expected to take place on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds of the offering will be approximately $4.5 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
  • Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering.
  • The offering will be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that Tonix may file with the SEC.

Tonix Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Thursday, September 28, 2023
Long COVID, Prader–Willi syndrome, Sumatriptan, Failure, Binge eating disorder, Telephone, Drug Master File, PPAR, Upsher-Smith Laboratories, Autoimmunity, Pain, Acquisition, Social anxiety disorder, Madison Avenue, Migraine, Psychiatry, Headache, Therapy, Capital market, SL, Research, Infection, Risk, Orphan drug, Security (finance), FDA, Long, COVID-19, Cancer, Smallpox, Disease, Government, Breakthrough therapy, Hydrogen chloride, MDD, Annual report, Gustav Neuring, Neurology, Form, CD40L, Obesity, Central nervous system, CNS, Sale, Prospectus, S-3, DSM-IV codes, Nature, Fibromyalgia, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering.

Key Points: 
  • CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering.
  • All of the securities to be sold in the offering are to be offered by Tonix.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the public offering, the timing and size of the public offering, the intended use of proceeds from the public offering and other statement that are predictive in nature.

Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023

Retrieved on: 
Thursday, September 14, 2023
Long COVID, Psychiatry, Prader–Willi syndrome, Headache, Central nervous system, Sumatriptan, Obesity, Failure, Therapy, Binge eating disorder, COVID-19, Infection, Cancer, Smallpox, PPAR, SL, Disease, Research, Risk, Upsher-Smith Laboratories, CNS, Autoimmunity, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Annual report, Gustav Neuring, Neurology, Social anxiety disorder, Fibromyalgia, Security (finance), FDA, Migraine, CD40L, Long, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.

Key Points: 
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.
  • Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates.
  • Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
  • Enrollment in a Phase 2 proof-of-concept study has been completed, and topline results were reported in the third quarter of 2023.

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

Retrieved on: 
Thursday, August 17, 2023
Long COVID, Psychiatry, Prader–Willi syndrome, Headache, Central nervous system, Sumatriptan, Obesity, Failure, Therapy, IR, Binge eating disorder, COVID-19, Infection, Cancer, Smallpox, PPAR, SL, Disease, Research, Risk, Upsher-Smith Laboratories, CNS, Autoimmunity, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Annual report, Neurology, Social anxiety disorder, Fibromyalgia, Security (finance), FDA, Migraine, CD40L, Long, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m.

Key Points: 
  • CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator.
  • A webcast of the presentation can be found here and will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Tonix Pharmaceuticals Announces Closing of $7 Million Public Offering

Retrieved on: 
Tuesday, August 1, 2023
Long COVID, Prader–Willi syndrome, Sumatriptan, Failure, Telephone, Drug Master File, Autoimmunity, Pain, Acquisition, Madison Avenue, Psychiatry, Therapy, Capital market, SL, Research, Infection, Risk, Orphan drug, Security (finance), FDA, COVID-19, Cancer, Smallpox, Disease, Government, Breakthrough therapy, Hydrogen chloride, MDD, Annual report, Neurology, Form, CD40L, Central nervous system, CNS, Sale, Prospectus, S-3, DSM-IV codes, Nature, Fibromyalgia, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

The gross proceeds of the offering were $7 million before deducting placement agent fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds of the offering were $7 million before deducting placement agent fees and other offering expenses payable by the Company.
  • Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent for the offering.
  • This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No.
  • The offering was made only by means of a prospectus supplement and accompanying base prospectus.